
Wugen
Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers. The company's technology offers engineered memory natural killer (NK) and CAR-T cell therapies...
Valuation
$245M
Latest known
Share Price
N/A
Total Raised
$323M
Last Round
N/A